Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The company will present findings on a novel GABAB receptor positive allosteric modulator for chronic cough at the Thirteenth London International Cough Symposium [1] - GABAB receptors are important in the cough neural circuit, and targeting them with allosteric modulators may offer advantages over traditional treatments like baclofen [2] Company Overview - Addex's lead drug candidate, ADX71149, is a positive allosteric modulator developed in collaboration with Janssen Pharmaceuticals and has completed several Phase 2 clinical studies [3] - The second clinical program, dipraglurant, is being evaluated for dyskinesia associated with Parkinson's disease and post-stroke recovery [3] - Addex is advancing a GABAB PAM program for chronic cough and has a partnership with Indivior for multiple drug candidates targeting substance use disorder [3] Research and Development - The upcoming presentation will focus on the antitussive activity of a novel GABAB receptor positive allosteric modulator in preclinical models [1] - GABAB receptor activation has been clinically validated with baclofen, but its use is limited due to side effects and tolerance issues [2] - Allosteric modulators are expected to provide higher selectivity and better tolerability compared to orthosteric compounds [2]
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)